Curis is a biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative therapeutics for the treatment of cancer. With a focus on hematologic malignancies and other cancers, Curis is committed to improving the lives of cancer patients through the development of differentiated therapies.
Through collaborations and scientific research, Curis is advancing a pipeline of potential treatments, including Emavusertib CA-4948, CI-8993, Fimepinostat, CA-170, CA-327, and Erivedge. With a strong emphasis on clinical studies and patient care, Curis aims to bring effective and life-changing therapies to market to address the unmet needs of cancer patients.
Generated from the website